Consolidated Statements of Comprehensive Loss-Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Net product revenue	$ 6,542	$ 8,351	$ 23,404	$ 23,763
Collaborative agreements	0	285,910	33	289,209
Royalties and other revenue	92	187	359	374
Total revenues	6,634	294,448	23,796	313,346
Operating expenses:
Cost of sales (including finite-lived intangible asset amortization)	633	577	1,929	2,457
Research and development, including stock-based compensation of $1,029 $1,698, $5,154 and $5,369, respectively	40,147	26,659	152,629	51,318
Selling, general and administrative expenses, included stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively	11,997	13,898	40,798	42,271
Asset Impairment Charges	0	28,638	0	28,638
Total operating expenses	52,777	69,772	196,956	124,684
Gain on sale of non-financial assets	132,818	0	132,818	0
Loss from operations	86,675	224,676	(40,342)	188,662
Gain (Loss) on Extinguishment of Debt	(255)	0	(255)	0
Interest expense	(4,118)	(5,204)	(14,374)	(15,485)
Interest and other income, net	301	600	1,892	2,080
Net Income (Loss) before Taxes	82,603	220,072	(53,079)	175,257
Income Tax Benefit	0	6,014	0	6,014
Net income (loss)	$ 82,603	$ 226,086	$ (53,079)	$ 181,271
Net income (loss) per common share, Basic	$ 0.77	$ 2.13	$ (0.50)	$ 1.71
Net income (loss) per common share, diluted	$ 0.71	$ 1.95	$ (0.50)	$ 1.59
Shares used in computing net loss per common share, Basic	107,309	106,272	106,974	106,200
Unrealized gain on investments	$ (277)	$ (50)	$ (49)	$ 48
Comprehensive loss	82,326	226,036	(53,128)	181,319
Stock-based compensation expense associated with research and development expense	1,029	1,698	5,154	5,369
Stock-based compensation expense associated with selling, general and administrative expense	875	1,864	5,440	5,370
Impairment of Real Estate	$ 0	$ 0	$ 1,600	0
Proceeds from Sale of Productive Assets				$ 0